Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-25-002083
Filing Date
2025-08-04
Accepted
2025-08-04 19:24:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 6272
2 ex1to13da112227019_080425.htm EX-1 2575
  Complete submission text file 0000921895-25-002083.txt   10463
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Subject) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-80136 | Film No.: 251182248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 44, TOWER 100, THE TOWERS WINSTON CHURCHILL, PAITILLA PANAMA CITY R1 07196
Business Address
Lazar David E. (Filed by) CIK: 0001932843 (see all company filings)

Type: SCHEDULE 13D/A